Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Depression Mild, Depression Moderate
Interventions
Yoga practice, Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Major Depressive Disorder
Interventions
Tocilizumab, Placebo, Whole-Body Hyperthermia
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major, Depression Mild
Interventions
MEB-001
Device
Lead sponsor
Medibio Limited
Industry
Eligibility
22 Years to 75 Years
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Bradenton, Florida • Blaine, Minnesota • Plymouth, Minnesota + 10 more
Completed Not applicable Interventional Results available

Cognitive Fitness for Depression in Older Adults

NCT04790630
Conditions
Depression Mild, Depressive Disorder, Major, Mild Cognitive Impairment
Interventions
Computerized Cognitive Remediation of Executive Functioning (CCR-EF), Active Control
Other
Lead sponsor
UConn Health
Other
Eligibility
60 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Conditions
PTSD, Post Traumatic Stress Disorder, Major Depressive Disorder, Traumatic Brain Injury
Interventions
IV ketamine, Midazolam
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
Interventions
Pramipexole ER, Escitalopram
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 20 more
Conditions
Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
Interventions
Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Mild-moderate Unipolar Depression; Persistent Negative Affect
Interventions
Mindfulness-Based Cognitive Therapy, Focused Attention (FA), Open- Monitoring
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Completed No phase listed Observational Accepts healthy volunteers

Glutamate Probes in Adolescent Depression

NCT02307617
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Centre for Addiction and Mental Health
Other
Eligibility
60 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York
Conditions
Major Depressive Disorder, Recurrent, Mild, Depressive Disorder, Major
Interventions
Transcranial Magnetic Stimulation (TMS), Magnetic Resonance Spectroscopy and Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Terminated No phase listed Observational Accepts healthy volunteers

MRS and Medication Response: A Pilot Study

NCT03254342
Conditions
Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Stanford, California
Conditions
Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions
es-citalopram, Memantine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New York, New York
Not listed No phase listed Observational Accepts healthy volunteers

Kintsugi Voice Device Pilot Study

NCT06374056
Conditions
Depression, Depression Moderate, Depression Severe, Depression Mild
Interventions
Kintsugi Voice Device
Device
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
22 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Berkeley, California
Conditions
Mild Cognitive Impairment (MCI), Depression
Interventions
Escitalopram, Memantine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Recruiting No phase listed Observational Accepts healthy volunteers

Kintsugi Voice Device Pivotal Study

NCT06809907
Conditions
Depression, Depression Moderate, Depression Severe, Depression Mild
Interventions
Kintsugi Voice Device
Device
Lead sponsor
Kintsugi Mindful Wellness, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Berkeley, California
Conditions
Major Depression, Mental Health
Interventions
Provigil
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
4
States / cities
Stanford, California • Atlanta, Georgia • New York, New York + 1 more
Conditions
Depression, Suicide and Self-harm, Depression in Adolescence, Depression Mild, Depression Moderate, Depression Severe
Interventions
Behavioral Activation
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of AGO178 in Participants With Liver Impairment

NCT01531309
Conditions
Hepatic Impairment
Interventions
AGO178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida